Live feed07:00:00·541dSave storyPRReleasevia QuantisnowAptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY TrialByQuantisnow·Wall Street's wire, on your screen.APTOAptose Biosciences Inc.Health Care